Sunday 8 March 2026

The Pharmaletter

Structure Therapeutics

A clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases.

Company Overview

Want to Update your Company's Profile?


Latest Structure Therapeutics News

Structure Therapeutics signs patent deal with Genentech
6 January 2026
GLP-1R gold rush: emerging biotechs set to challenge market leaders
14 January 2025
GentiBio names Mark Bach as chief medical officer
30 September 2024
New chief medical officer at Structure Therapeutics
18 September 2024
More Structure Therapeutics news >


Today's issue

CBER chief Vinay Prasad to quit
Biotechnology
CBER chief Vinay Prasad to quit
7 March 2026
Pharmaceutical
FDA meeting with States on importation of lower cost drugs
7 March 2026
Pharmaceutical
Sciwind Biosciences wins China approval for ecnoglutide injection
6 March 2026
Pharmaceutical
Servier to acquire Day One Biopharma
6 March 2026
Biotechnology
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam
6 March 2026
Biotechnology
Approval of J&J combo ‘potential SOC as early as second line’
6 March 2026
Pharmaceutical
Nautilus names Amber Faust VP of sales
6 March 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze